文献速递头颈介入技术与安全US

抗血小板或抗凝治疗患者头颈部肿块病变的超声引导粗针活检初步报告

Ultrasound-Guided Core Needle Biopsy for Head and Neck Mass Lesions in Patients Undergoing Antiplatelet or Anticoagulation Therapy: A Preliminary Report.
PubMed 文献 · J Ultrasound Med · 2017-04-03

前瞻性病例研究纳入146例连续接受超声引导粗针活检的头颈部肿块患者,其中32例正在接受抗血小板/抗凝治疗(阿司匹林、氯吡格雷、西洛他唑、华法林)。两组均无临床出血/血肿,仅超声发现的亚临床出血/血肿及取材不满意率均无显著差异;作者认为超声引导粗针活检安全且诊断结果良好,无需停用抗血小板/抗凝治疗,但为初步研究、队列相对较小,需更大研究证实。

要点

  • 抗血小板/抗凝治疗组与未治疗组均无临床出血/血肿,仅超声发现的亚临床出血/血肿无显著差异(P = .229)。
  • 两组取材不满意率无显著差异(P > .999)。
  • 将阿司匹林患者(n = 18)重新归入无抗血小板/抗凝治疗组后,与氯吡格雷、西洛他唑或华法林患者(n = 14)相比并发症发生率仍无显著差异。

核心结论

  • 作者认为超声引导粗针活检安全且诊断结果良好,在头颈部肿块病变患者中无需停用抗血小板/抗凝治疗;但为初步研究、队列相对较小,需更大研究证实。

研究设计与样本

  • 前瞻性病例研究,纳入146例连续接受超声引导粗针活检的头颈部肿块病变患者,其中32例正在接受抗血小板/抗凝治疗(阿司匹林、氯吡格雷、西洛他唑、华法林)。

诊断标准与关键数值

  • 两组均无临床出血/血肿;仅超声检查发现的亚临床出血/血肿在两组间无显著差异(P = .229)。
  • 两组取材不满意率无显著差异(P > .999)。
  • 将阿司匹林患者(n = 18)重新归入无抗血小板/抗凝治疗组后,与氯吡格雷、西洛他唑或华法林患者(n = 14)相比并发症发生率仍无显著差异。

临床应用与阅片要点

  • 作者认为超声引导粗针活检安全且诊断结果良好,在头颈部肿块病变患者中无需停用抗血小板/抗凝治疗。
  • 作者指出本研究为初步研究、队列相对较小,需更大研究证实其发现。

局限性

  • 作者指出本研究为初步研究,队列相对较小。
  • 作者指出需更大研究证实其发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: We compared the complications and diagnostic adequacy of ultrasound (US)-guided core needle biopsy (CNB) for head and neck mass lesions between patients who did and did not receive antiplatelet/anticoagulation therapy.

METHODS: This study was designed as a prospective case study including 146 consecutive patients who underwent US-guided CNB for head and neck mass lesions. Of these, 32 patients were undergoing antiplatelet/anticoagulation therapy involving aspirin, clopidogrel, cilostazol, and warfarin.

RESULTS: None of the patients had clinical bleeding/hematoma in either group. Subclinical bleeding/hematoma recognized only by a US examination was not significantly different between the groups (P = .229). No other complications were noticed. The rate of unsatisfactory sampling was also not different between the groups (P > .999). Furthermore, when patients receiving aspirin (n = 18) were reclassified into the no-antiplatelet/anticoagulation therapy group, there was still no significant difference in the incidences of complications compared with the patients receiving clopidogrel, cilostazol, or warfarin (n = 14).

CONCLUSIONS: Our study suggests that US-guided CNB is safe and provides good diagnostic results without necessitating the discontinuation of antiplatelet/anticoagulation therapy in patients with head and neck mass lesions. However, as this was a preliminary study, the cohort was relatively small. Larger studies are needed to confirm our findings.

来源:J Ultrasound Med,查看原文。版权归原作者所有。

引用

  1. Ahn D, Roh JH, Kim JK, et al. Ultrasound-Guided Core Needle Biopsy for Head and Neck Mass Lesions in Patients Undergoing Antiplatelet or Anticoagulation Therapy: A Preliminary Report. J Ultrasound Med. 2017. PMID: 28370160. doi:10.7863/ultra.16.05045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。